BriaCell Therapeutics Announces Closing of Public Offering
BriaCell Therapeutics (Nasdaq: BCTX) has completed its previously announced best-efforts public offering, selling 762,500 common shares at $4.00 per share, raising gross proceeds of $3.05 million. The offering was conducted under the Company's effective shelf registration statement on Form S-3, with ThinkEquity serving as the sole placement agent.
The clinical-stage biotechnology company, which develops novel immunotherapies for cancer treatment, plans to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives. The offering was executed under the TSX Company Manual Section 602.1 exemption, applicable to eligible interlisted issuers on recognized exchanges like Nasdaq.
BriaCell Therapeutics (Nasdaq: BCTX) ha completato l'offerta pubblica di vendita a migliori sforzi precedentemente annunciata, vendendo 762.500 azioni ordinarie a 4,00 $ per azione, raccogliendo proventi lordi di 3,05 milioni di dollari. L'offerta è stata effettuata sotto la dichiarazione di registrazione efficace della Società in base al modulo S-3, con ThinkEquity che ha funto da unico agente di collocamento.
L'azienda biotecnologica in fase clinica, che sviluppa nuove immunoterapie per il trattamento del cancro, prevede di utilizzare i proventi netti per le esigenze di capitale circolante, scopi aziendali generali e per far progredire i propri obiettivi aziendali. L'offerta è stata eseguita in base all'esenzione della Sezione 602.1 del Manuale delle Aziende TSX, applicabile agli emittenti interlistati idonei su borse riconosciute come Nasdaq.
BriaCell Therapeutics (Nasdaq: BCTX) ha completado su oferta pública de venta a mejores esfuerzos previamente anunciada, vendiendo 762,500 acciones ordinarias a 4.00 $ por acción, recaudando ingresos brutos de 3.05 millones de dólares. La oferta se realizó bajo la declaración de registro efectiva de la Compañía en el formulario S-3, con ThinkEquity actuando como el único agente de colocación.
La empresa biotecnológica en etapa clínica, que desarrolla nuevas inmunoterapias para el tratamiento del cáncer, planea utilizar los ingresos netos para requisitos de capital de trabajo, propósitos corporativos generales y para avanzar en sus objetivos comerciales. La oferta se ejecutó bajo la exención de la Sección 602.1 del Manual de Empresas TSX, aplicable a emisores interlistados elegibles en mercados reconocidos como Nasdaq.
BriaCell Therapeutics (Nasdaq: BCTX)은 이전에 발표된 최선의 노력을 통한 공모를 완료하고, 762,500주 일반 주식을 주당 4.00달러에 판매하여 총 3.05백만 달러의 수익을 올렸습니다. 이 공모는 회사의 유효한 선반 등록 성명서 S-3에 따라 진행되었으며, ThinkEquity가 유일한 배치 대행사로 활동했습니다.
암 치료를 위한 새로운 면역 요법을 개발하는 임상 단계 생명공학 회사는 순수익을 운영 자본 요구 사항, 일반 기업 목적 및 사업 목표를 추진하는 데 사용할 계획입니다. 이 공모는 Nasdaq과 같은 인정된 거래소에서 적격 상장된 발행자에게 적용되는 TSX 회사지침 602.1 섹션의 면제에 따라 실행되었습니다.
BriaCell Therapeutics (Nasdaq: BCTX) a complété son offre publique de vente à meilleurs efforts précédemment annoncée, vendant 762 500 actions ordinaires à 4,00 $ par action, levant des produits bruts de 3,05 millions de dollars. L'offre a été réalisée sous la déclaration d'enregistrement efficace de la Société sur le formulaire S-3, avec ThinkEquity agissant en tant qu'agent de placement unique.
La société de biotechnologie en phase clinique, qui développe de nouvelles immunothérapies pour le traitement du cancer, prévoit d'utiliser les produits nets pour les besoins en fonds de roulement, les objectifs généraux de l'entreprise et pour faire avancer ses propres objectifs commerciaux. L'offre a été exécutée en vertu de l'exemption de la Section 602.1 du Manuel des entreprises TSX, applicable aux émetteurs interlistés éligibles sur des bourses reconnues telles que Nasdaq.
BriaCell Therapeutics (Nasdaq: BCTX) hat das zuvor angekündigte öffentliche Angebot nach besten Bemühungen abgeschlossen und 762.500 Stammaktien zu je 4,00 $ verkauft, wodurch Bruttoeinnahmen von 3,05 Millionen Dollar erzielt wurden. Das Angebot wurde gemäß der effektiven Registrierungsanmeldung der Gesellschaft auf Formular S-3 durchgeführt, wobei ThinkEquity als alleiniger Platzierungsagent fungierte.
Das biopharmazeutische Unternehmen in der klinischen Phase, das neuartige Immuntherapien zur Krebsbehandlung entwickelt, plant, die Nettoerlöse für Betriebskapitalbedarfe, allgemeine Unternehmenszwecke und zur Förderung seiner Geschäftsziele zu nutzen. Das Angebot wurde gemäß der Ausnahme der Sektion 602.1 des TSX Unternehmenshandbuchs durchgeführt, die für berechtigte intergelistete Emittenten an anerkannten Börsen wie Nasdaq gilt.
- Secured $3.05 million in gross proceeds from public offering
- Successfully completed share offering at $4.00 per share
- Dilution of existing shareholders through issuance of 762,500 new shares
Insights
BriaCell's latest
The offering's timing and structure through a shelf registration (Form S-3) demonstrates proactive financial planning, allowing for quick market access. For clinical-stage biotechs, maintaining adequate cash reserves is crucial, as development costs can range from
Notably, the company's dual-listing status (Nasdaq/TSX) and utilization of Section 602.1 of TSX Manual streamlined the offering process, potentially reducing transaction costs. The engagement of ThinkEquity as sole placement agent suggests a focused distribution strategy targeting specialized biotech investors. For existing shareholders, while there is immediate dilution, the strengthened balance sheet enhances BriaCell's negotiating position for potential future partnerships or additional financing rounds.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
ThinkEquity acted as sole placement agent for the offering.
The securities were offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering was made by means of a prospectus supplement and prospectus which have been filed with the SEC and are available on the SEC’s website at www.sec.gov. You should read the applicable prospectus supplement and prospectus for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting the SEC website at www.sec.gov. Alternatively, you may obtain copies by contacting ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the use of proceeds from the offering, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risk Factors” in the Company’s prospectus supplement for the offering and most recent Annual Report on Form 10-K, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
How much did BriaCell (BCTX) raise in its February 2025 public offering?
What is the purpose of BriaCell's (BCTX) February 2025 public offering?
How many shares did BriaCell (BCTX) sell in its February 2025 offering?
What was the price per share for BriaCell's (BCTX) February 2025 public offering?
Who was the placement agent for BriaCell's (BCTX) February 2025 public offering?
